<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font21 { font-size : 21; } .font22 { font-size : 22; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">pulmonary </span>
   <span class="font22">children </span>
   <span class="font21">arterial </span>
   <span class="font18">hypertension </span>
   <span class="font17">PAH </span>
   <span class="font16">sildenafil </span>
   <span class="font16">patients </span>
   <span class="font16">pediatric </span>
   <span class="font15">treatment </span>
   <span class="font14">therapy </span>
   <span class="font14">hypertension. </span>
   <span class="font14">study </span>
   <span class="font13">Respir </span>
   <span class="font13">clinical </span>
   <span class="font13">riociguat </span>
   <span class="font13">hypertension: </span>
   <span class="font13">{border-style </span>
   <span class="font12">efficacy </span>
   <span class="font12">Cardiol. </span>
   <span class="font12">Eur </span>
   <span class="font12">disease </span>
   <span class="font12">px;} </span>
   <span class="font12">#ffffff;} </span>
   <span class="font12">Pulmonary </span>
   <span class="font12">Ivy </span>
   <span class="font12">combination </span>
   <span class="font12">heart </span>
   <span class="font12">tadalafil </span>
   <span class="font12">use </span>
   <span class="font12">PAH. </span>
   <span class="font12">bosentan </span>
   <span class="font12">children. </span>
   <span class="font12">Sildenafil </span>
   <span class="font12">Med. </span>
   <span class="font12">PAH, </span>
   <span class="font12">data </span>
   <span class="font12">oral </span>
   <span class="font11">Beghetti </span>
   <span class="font11">long‐term </span>
   <span class="font11">survival </span>
   <span class="font11">vascular </span>
   <span class="font11">(age, </span>
   <span class="font11">European </span>
   <span class="font11">PDEi </span>
   <span class="font11">Pediatr </span>
   <span class="font11">associated </span>
   <span class="font11">improved </span>
   <span class="font11">paediatric </span>
   <span class="font11">review </span>
   <span class="font11">trials </span>
   <span class="font11">Bayer </span>
   <span class="font11">Treatment </span>
   <span class="font11">idiopathic </span>
   <span class="font11">pressure </span>
   <span class="font11">safety </span>
   <span class="font11">significant </span>
   <span class="font11">tid) </span>
   <span class="font11">AG, </span>
   <span class="font11">Heart </span>
   <span class="font11">Pediatric </span>
   <span class="font11">artery </span>
   <span class="font11">mPAP </span>
   <span class="font11">response </span>
   <span class="font11">studies </span>
   <span class="font11">(– mg </span>
   <span class="font11">Berger </span>
   <span class="font11">Circulation. </span>
   <span class="font11">Heart. </span>
   <span class="font11">P = .) </span>
   <span class="font11">adolescents </span>
   <span class="font11">adults </span>
   <span class="font11">compared </span>
   <span class="font11">exercise </span>
   <span class="font11">including </span>
   <span class="font11">pathway </span>
   <span class="font11">px; </span>
   <span class="font11">registry </span>
   <span class="font11">surgery </span>
   <span class="font11">tolerability </span>
   <span class="font11">{font-family </span>
   <span class="font11">(Group </span>
   <span class="font11">Actelion </span>
   <span class="font11">Coll </span>
   <span class="font11">Haworth </span>
   <span class="font11">MWD </span>
   <span class="font11">Tadalafil </span>
   <span class="font11">adverse </span>
   <span class="font11">cardiac </span>
   <span class="font11">congenital </span>
   <span class="font11">diagnosis </span>
   <span class="font11">effects </span>
   <span class="font11">events </span>
   <span class="font11">font-size </span>
   <span class="font11">hemodynamic </span>
   <span class="font11">however, </span>
   <span class="font11">improve </span>
   <span class="font11">include </span>
   <span class="font11">infants </span>
   <span class="font11">low </span>
   <span class="font11">mean </span>
   <span class="font11">open‐label </span>
   <span class="font11">prostacyclin </span>
   <span class="font11">receptor </span>
   <span class="font11">reduced </span>
   <span class="font11">reported </span>
   <span class="font11">sGC </span>
   <span class="font11">severe </span>
   <span class="font11">tolerated </span>
   <span class="font11">trial </span>
   <span class="font10">Barst </span>
   <span class="font10">Bonnet </span>
   <span class="font10">Cardiology </span>
   <span class="font10">Care </span>
   <span class="font10">Circ. </span>
   <span class="font10">Crit </span>
   <span class="font10">Douwes </span>
   <span class="font10">Drug </span>
   <span class="font10">Ghofrani </span>
   <span class="font10">Humpl </span>
   <span class="font10">Hypertension </span>
   <span class="font10">PATENT‐CHILD </span>
   <span class="font10">PVO </span>
   <span class="font10">Patients </span>
   <span class="font10">Pulm </span>
   <span class="font10">Sitbon </span>
   <span class="font10">World </span>
   <span class="font10">acute </span>
   <span class="font10">children, </span>
   <span class="font10">cyclase </span>
   <span class="font10">difference </span>
   <span class="font10">double; </span>
   <span class="font10">extension </span>
   <span class="font10">functional </span>
   <span class="font10">generally </span>
   <span class="font10">guanylate </span>
   <span class="font10">improvement </span>
   <span class="font10">initial </span>
   <span class="font10">lung </span>
   <span class="font10">management </span>
   <span class="font10">open‐label, </span>
   <span class="font10">oxygen </span>
   <span class="font10">prognosis </span>
   <span class="font10">received </span>
   <span class="font10">results </span>
   <span class="font10">years </span>
   <span class="font10">Clin </span>
   <span class="font10">Clinical </span>
   <span class="font10">Data </span>
   <span class="font10">Diagnosis </span>
   <span class="font10">ERAs </span>
   <span class="font10">FC, </span>
   <span class="font10">Int </span>
   <span class="font10">NO‐sGC‐cGMP </span>
   <span class="font10">PAH‐targeted </span>
   <span class="font10">Paediatric </span>
   <span class="font10">Riociguat </span>
   <span class="font10">STARTS‐ </span>
   <span class="font10">Sabri </span>
   <span class="font10">University </span>
   <span class="font10">[], </span>
   <span class="font10">ambrisentan </span>
   <span class="font10">and/or </span>
   <span class="font10">blood </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">cGMP </span>
   <span class="font10">cases </span>
   <span class="font10">considered </span>
   <span class="font10">dose, </span>
   <span class="font10">endothelin </span>
   <span class="font10">epoprostenol </span>
   <span class="font10">findings </span>
   <span class="font10">high </span>
   <span class="font10">http://orcid.org/--- </span>
   <span class="font10">hypertension; </span>
   <span class="font10">iPAH </span>
   <span class="font10">iloprost </span>
   <span class="font10">improvements </span>
   <span class="font10">increased </span>
   <span class="font10">inhaled </span>
   <span class="font10">licensed </span>
   <span class="font10">medium </span>
   <span class="font10">natriuretic </span>
   <span class="font10">new </span>
   <span class="font10">outcomes </span>
   <span class="font10">peptide </span>
   <span class="font10">placebo </span>
   <span class="font10">previously </span>
   <span class="font10">primary </span>
   <span class="font10">receiving </span>
   <span class="font10">solid; </span>
   <span class="font10">suggested </span>
   <span class="font10">switching </span>
   <span class="font10">testing </span>
   <span class="font10">times </span>
   <span class="font10">treated </span>
   <span class="font10">using </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10"> mg/kg/day </span>
   <span class="font10">( mg </span>
   <span class="font10">. mg </span>
   <span class="font10">Adempas </span>
   <span class="font10">CHD </span>
   <span class="font10">Children </span>
   <span class="font10">Eli </span>
   <span class="font10">Engl </span>
   <span class="font10">Grimminger </span>
   <span class="font10">Hislop </span>
   <span class="font10">Hoeper </span>
   <span class="font10">Hospital </span>
   <span class="font10">Initial </span>
   <span class="font10">Long‐term </span>
   <span class="font10">Moledina </span>
   <span class="font10">PAH‐CHD </span>
   <span class="font10">PATENT‐ </span>
   <span class="font10">Pediatr. </span>
   <span class="font10">Pharmaceuticals, </span>
   <span class="font10">Pharmacol </span>
   <span class="font10">Rev. </span>
   <span class="font10">Rosenzweig </span>
   <span class="font10">Safety </span>
   <span class="font10">Schulze‐Neick </span>
   <span class="font10">Suppl </span>
   <span class="font10">Takatsuki </span>
   <span class="font10">Ther. </span>
   <span class="font10">Zijlstra </span>
   <span class="font10">[last </span>
   <span class="font10">accessed </span>
   <span class="font10">adults, </span>
   <span class="font10">analysis </span>
   <span class="font10">based </span>
   <span class="font10">baseline </span>
   <span class="font10">bold </span>
   <span class="font10">bone </span>
   <span class="font10">channel </span>
   <span class="font10">chronic </span>
   <span class="font10">collab: </span>
   <span class="font10">consensus </span>
   <span class="font10">courier; </span>
   <span class="font10">decreased </span>
   <span class="font10">drugs </span>
   <span class="font10">em; </span>
   <span class="font10">endorsed </span>
   <span class="font10">endpoint) </span>
   <span class="font10">endpoints </span>
   <span class="font10">evaluated </span>
   <span class="font10">evaluation </span>
   <span class="font10">evidence </span>
   <span class="font10">experience </span>
   <span class="font10">exploratory </span>
   <span class="font10">goals </span>
   <span class="font10">guanosine </span>
   <span class="font10">hemodynamics </span>
   <span class="font10">inhibitors </span>
   <span class="font10">levels </span>
   <span class="font10">mPAP, </span>
   <span class="font10">million </span>
   <span class="font10">monotherapy </span>
   <span class="font10">muscle </span>
   <span class="font10">oxide </span>
   <span class="font10">parameters </span>
   <span class="font10">phosphodiesterase </span>
   <span class="font10">pilot </span>
   <span class="font10">post </span>
   <span class="font10">pre‐ </span>
   <span class="font10">prostanoid </span>
   <span class="font10">prostanoids </span>
   <span class="font10">pt;} </span>
   <span class="font10">randomized </span>
   <span class="font10">receptors </span>
   <span class="font10">resistance </span>
   <span class="font10">retrospective </span>
   <span class="font10">right </span>
   <span class="font10">role </span>
   <span class="font10">safety, </span>
   <span class="font10">septal </span>
   <span class="font10">sildenafil, </span>
   <span class="font10">smooth </span>
   <span class="font10">statement </span>
   <span class="font10">strategies </span>
   <span class="font10">study. </span>
   <span class="font10">syndrome </span>
   <span class="font10">systolic </span>
   <span class="font10">therapeutic </span>
   <span class="font10">treatments </span>
   <span class="font10">treprostinil </span>
   <span class="font10">trials, </span>
   <span class="font10">type </span>
   <span class="font10">used </span>
   <span class="font10">walking </span>
   <span class="font10">years, </span>
   <span class="font10">young </span>
   <span class="font10">‐minute </span>
  </p>
 </body>
</html>
